SecSonar.com

Standard BioTools Inc. (LAB)

Standard BioTools Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Standard BioTools Inc. (LAB) is a Medical - Devices company based in US with a market capitalization of $450.9M. Revenue declined 51.1% year-over-year and free cash flow was negative at -$82.7M. This page tracks LAB's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 814 employees · IPO Feb 10, 2011

Valuation

Valuation & price

$0.98 · as of May 17, 2026 · -41.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.06

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$1.68$1.21$0.73Jul 25Dec 25Jul 26Jul 7, 25$1.28Jul 9, 25$1.36Jul 11, 25$1.32Jul 15, 25$1.22Jul 17, 25$1.25Jul 21, 25$1.26Jul 23, 25$1.45Jul 25, 25$1.40Jul 29, 25$1.39Jul 31, 25$1.33Aug 4, 25$1.32Aug 6, 25$1.28Aug 11, 25$1.28Aug 13, 25$1.31Aug 15, 25$1.23Aug 19, 25$1.27Aug 21, 25$1.20Aug 25, 25$1.24Aug 27, 25$1.28Aug 29, 25$1.26Sep 3, 25$1.29Sep 5, 25$1.30Sep 9, 25$1.28Sep 11, 25$1.33Sep 16, 25$1.38Sep 18, 25$1.41Sep 22, 25$1.40Sep 24, 25$1.31Sep 26, 25$1.30Sep 30, 25$1.30Oct 2, 25$1.28Oct 6, 25$1.32Oct 8, 25$1.32Oct 10, 25$1.28Oct 14, 25$1.31Oct 16, 25$1.29Oct 21, 25$1.32Oct 23, 25$1.38Oct 27, 25$1.32Oct 29, 25$1.19Oct 31, 25$1.20Nov 4, 25$1.19Nov 6, 25$1.12Nov 10, 25$1.17Nov 12, 25$1.18Nov 14, 25$1.24Nov 18, 25$1.24Nov 20, 25$1.28Nov 25, 25$1.42Nov 28, 25$1.50Dec 2, 25$1.42Dec 4, 25$1.44Dec 8, 25$1.46Dec 10, 25$1.47Dec 12, 25$1.45Dec 16, 25$1.49Dec 18, 25$1.66Dec 22, 25$1.68Dec 24, 25$1.47Dec 29, 25$1.28Jan 2, 26$1.27Jan 6, 26$1.27Jan 8, 26$1.54Jan 12, 26$1.51Jan 14, 26$1.59Jan 16, 26$1.56Jan 21, 26$1.64Jan 23, 26$1.55Jan 27, 26$1.48Jan 29, 26$1.41Feb 2, 26$1.41Feb 4, 26$1.28Feb 9, 26$1.26Feb 11, 26$1.19Feb 13, 26$1.12Feb 18, 26$1.14Feb 20, 26$1.13Feb 24, 26$1.15Feb 26, 26$1.17Mar 2, 26$1.10Mar 4, 26$1.06Mar 6, 26$0.99Mar 10, 26$0.99Mar 12, 26$0.93Mar 17, 26$0.98Mar 19, 26$0.96Mar 23, 26$0.97Mar 25, 26$0.96Mar 27, 26$0.90Mar 31, 26$0.92Apr 2, 26$0.91Apr 7, 26$0.93Apr 9, 26$0.91Apr 13, 26$0.88Apr 15, 26$0.98Apr 17, 26$0.93Apr 22, 26$0.94Apr 24, 26$0.90Apr 28, 26$0.92Apr 30, 26$0.93May 4, 26$0.94May 6, 26$0.97May 8, 26$1.02May 12, 26$1.01May 14, 26$1.00May 18, 26$0.99May 20, 26$1.06May 22, 26$1.03May 28, 26$1.14Jun 1, 26$1.15Jun 3, 26$1.14Jun 5, 26$1.15Jun 9, 26$0.89Jun 11, 26$0.91Jun 15, 26$0.85Jun 17, 26$0.81Jun 22, 26$0.77Jun 24, 26$0.75Jun 26, 26$0.73Jul 2, 26$0.91
$0.7352-week range$1.68
Loading valuation history…

Fundamentals

Key fundamentals

$450.9M

Market cap

-51.1%

Revenue growth (YoY)

49.9%

Gross margin

-$82.7M

Free cash flow (USD)

-$156.7M

Net debt

Net cash position

8.2%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$104.4MFY 2017$101.9MFY 2018$113.0MFY 2019$117.2MFY 2020$138.1MFY 2021$130.6MFY 2022$97.9MFY 2023$106.3MFY 2024$174.4MFY 2025$85.3M
$104.4M$85.3M

Free cash flow by year

2016 → 2025

FY 2016$-44.2MFY 2017$-25.7MFY 2018$-25.6MFY 2019$-37.7MFY 2020$-28.1MFY 2021$-57.3MFY 2022$-93.2MFY 2023$-46.1MFY 2024$-151.8MFY 2025$-82.7M
-$44.2M-$82.7M

Gross margin by year

2021 → 2025

FY 202153.1%FY 202237.8%FY 202347.4%FY 202448.3%FY 202549.9%
53.1%49.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventEquity Incentive PlanJun 18, 2026Filing
  • 8-K eventMerger AgreementJun 8, 2026Filing
  • 8-K eventRegained Nasdaq ComplianceJun 5, 2026Filing
  • 8-K eventRSU GrantJun 3, 2026Filing
  • 8-K eventChange of Control PlanMay 28, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing
  • 8-K eventDelisting NoticeApr 24, 2026Filing

Questions

Frequently asked questions

What is Standard BioTools Inc.'s market cap?

Standard BioTools Inc. (LAB) has a market capitalization of $450.9M.

What is LAB's P/E ratio?

A meaningful P/E ratio is not available for LAB — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is LAB's price-to-book (P/B) ratio?

LAB trades at 1.06 times book value per share.

Are insiders buying LAB stock?

SEC Form 4 filings show no open-market insider buys at Standard BioTools Inc. in the last 90 days (0 sells).

Same arena

Related companies in Medical - Devices

KIDS

OrthoPediatrics Corp.

$449.3M

VREX

Varex Imaging Corporation

$434.5M

PACB

Pacific Biosciences of California, Inc.

$469.2M

OFIX

Orthofix Medical Inc.

$382.1M

VMD

Viemed Healthcare, Inc.

$381.1M

CLPT

ClearPoint Neuro, Inc.

$368.9M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.